tradingkey.logo

Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy

ReutersApr 2, 2025 10:05 AM

- Edgewise Therapeutics Inc EWTX.O:

  • EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 CIRRUS-HCM FOUR-WEEK TRIAL OF EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY (HCM)

  • EDGEWISE THERAPEUTICS INC - EDG-7500 WAS GENERALLY WELL-TOLERATED

  • EDGEWISE THERAPEUTICS INC: INITIAL DATA READ-OUT FROM PART D IS EXPECTED IN SECOND HALF OF 2025

  • EDGEWISE: TRIAL SHOWED CLINICALLY MEANINGFUL REDUCTIONS IN LVOT GRADIENTS IN PARTICIPANTS WITH OBSTRUCTIVE HCM

  • EDGEWISE THERAPEUTICS INC - PHASE 3 INITIATION PLANNED FOR FIRST HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI